An NCI-funded clinical trial has shown that treatment-related early deaths among people with a rare leukemia can be greatly reduced. How did they do it? In part, by starting a help desk staffed by experts in treating this cancer.
Two research teams have developed ways of improving CAR T-cell therapies, including ways to make them effective against solid tumors like pancreatic cancer and melanoma.
The Food and Drug Administration (FDA) approved tucatinib (Tukysa) with trastuzumab (Herceptin) to treat HER2-positive advanced colorectal cancer. The approval was based on the MOUNTAINEER trial, in which nearly 40% of participants’ tumors shrank after receiving the drugs.
We’ve added a drug summary for elacestrant dihydrochloride (Orserdu). FDA recently approved this drug to treat breast cancer in certain women and men that is ER positive and HER2 negative, has a mutation in the ESR1 gene, has spread, and has gotten worse after treatment with hormone therapy.
Controlling pain is an important part of your cancer treatment plan. Learn how to track your levels of pain and how acupuncture, biofeedback, and physical therapy can help treat it.
Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.
